Hostname: page-component-848d4c4894-jbqgn Total loading time: 0 Render date: 2024-06-23T17:08:39.178Z Has data issue: false hasContentIssue false
  • English
  • Français

P02.319 Antipsychotic treatment, adverse events and health-related quality of life

Published online by Cambridge University Press:  16 April 2020

X. Badia ,
A. Casado ,
J.A. Sacristán ,
J.C. Gómez ,
K.J. Gregor  and
S. Gavart
X. Badia
Affiliation:
The EFESO Study Group; Public Health Institute of Catalonia, Barcelona
A. Casado
Affiliation:
The EFESO Study Group; Public Health Institute of Catalonia, Barcelona
J.A. Sacristán
Affiliation:
Clinical Research Department Lilly S. A., Madrid, Spain
J.C. Gómez
Affiliation:
Clinical Research Department Lilly S. A., Madrid, Spain
K.J. Gregor
Affiliation:
The EFESO Study Group; Public Health Institute of Catalonia, Barcelona
S. Gavart
Affiliation:
Eli Lilly and Company, UK

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Symposia
Information
European Psychiatry , Volume 15 , Issue S2: Congress of the Association of European Psychiatrists , October 2000 , pp. 408s
Copyright
Copyright © European Psychiatric Association 2000
Submit a response

Comments

No Comments have been published for this article.